Davis R M Inc. lessened its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 7.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 26,498 shares of the exchange traded fund’s stock after selling 2,083 shares during the period. Davis R M Inc.’s holdings in SPDR S&P Biotech ETF were worth $2,618,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in XBI. Tidemark LLC grew its holdings in SPDR S&P Biotech ETF by 101.5% during the third quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock worth $39,000 after acquiring an additional 199 shares during the period. ORG Partners LLC acquired a new position in shares of SPDR S&P Biotech ETF during the 2nd quarter worth $40,000. Quintet Private Bank Europe S.A. purchased a new position in shares of SPDR S&P Biotech ETF in the 3rd quarter valued at about $40,000. ORG Wealth Partners LLC acquired a new stake in shares of SPDR S&P Biotech ETF in the third quarter valued at about $44,000. Finally, Howe & Rusling Inc. purchased a new stake in SPDR S&P Biotech ETF during the third quarter worth about $49,000.
SPDR S&P Biotech ETF Trading Up 1.4 %
Shares of SPDR S&P Biotech ETF stock opened at $97.63 on Tuesday. The company has a 50-day moving average of $98.37 and a two-hundred day moving average of $96.38. SPDR S&P Biotech ETF has a 12-month low of $71.99 and a 12-month high of $105.47. The stock has a market cap of $7.44 billion, a PE ratio of 11.47 and a beta of 1.11.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- The 3 Best Blue-Chip Stocks to Buy Now
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- What Investors Need to Know About Upcoming IPOs
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- What is a support level?
- Discover the 3 Best Performing Stocks That Went Public in 2024
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.